Matthew Baker, Ph.D work email
- Valid
Matthew Baker, Ph.D personal email
::: GLOBAL SCIENCE & BUSINESS DEVELOPMENT EXECUTIVE :::Global reputation for driving immunology advancements with a special focus on immunotherapy, small molecule oncology drugs and large molecule drug immunogenicity. Impressive track record of producing novel and proprietary technologies for engineering antibodies and assessing drug immunogenicity. Knowledgeable in small molecule drug discovery/development, antibody drug conjugates and experienced in preclinical drug development programs that have entered clinical trials. Respected for negotiating 150+ business deals, leading teams of 60+ staff members, and controlling multimillion-dollar budgets. Exceptionally well-versed in all aspects of strategic business development with an impressive track record of generating multimillion-dollar turnover and expanding revenue streams. Highly effective in simplifying complex concepts and delivering persuasive presentations to investors. History of identifying and drafting strategic business plans for M&A targets.Successful entrepreneur with extensive experience in the development, mentoring, and leadership of personnel. Authored 30+ publications and generated 21 published patents. Invited to speak at 50+ global conferences.::: SIGNATURE STRENGTHS :::• Proprietary Technologies• Research & Development• Budgeting & Cost Controls• Business Development & Planning• Contract Preparations, Negotiations, & Reviews• Project Management• Strategic Planning• Cross-Functional Team Leadership• Performance Improvements & Quality Management• Investor & Vendor Relationship Cultivation
-
Chief Executive OfficerLaigo BioCambridge, Gb
-
Startup Acting CeoArgobio Oct 2024 - PresentParis, FrArgoBio Studio specializes in building therapeutics-focused companies by providing early-stage investment for translational research projects and supporting the corporate and strategic development of its portfolio companies. As Acting CEOs, we guide early-stage biotech startups through the investment process, helping them achieve key milestones to successfully secure Series A funding. ArgoBio Studio is funded by BPI France, Kumar Partners, Angelina Ventures, Evotec and Institute Pasteur. -
Non Executive DirectorFusion Antibodies Mar 2022 - PresentBelfast, Northern Ireland, Gb -
Chief Executive OfficerNeophore Ltd Jan 2020 - Jul 2024Cambridge, Cambridgeshire, Gb -
Vice President ImmunologyNeophore Ltd May 2019 - Jan 2020Cambridge, Cambridgeshire, GbNeoPhore is creating novel small molecule immuno-oncology therapeutics by targeting the DNA mismatch repair (MMR) pathway. MMR deficiency is known to enhance immunotherapy induced immunity in solid tumors by engaging patients immune system through the generation of neoantigens. NeoPhore's small molecule MMR inhibitors will enable previously immunotherapy resistant patients to be treated with immune checkpoint inhibitors known to generate robust and durable responses.
-
Non Executive DirectorOxford Genetics Ltd Aug 2016 - Mar 2021Oxford, Oxfordshire, GbA synthetic biology company specializing in DNA design, protein expression optimization, antibody discovery and cell line development technologies and services. Acquired by WuXi Apptech in March 2021. -
Chief Scientific OfficerDenceptor Therapeutics Jul 2016 - Feb 2018Co-founder of Denceptor Therapeutics (a joint venture between Baylor Institute for Immunology Research and Abzena) to develop antibody based dendritic cell targeted immunotherapies for cancer and autoimmune diseases.
-
Vp Oncology And ImmunologyCelentyx Ltd Oct 2016 - Jul 2017Birmingham, GbCelentyx (based at The University of Birmingham UK) is focused on determining the mechanism of action, toxicity and efficacy of immune targeting drugs in oncology and autoimmune/inflammatory indications. Key aspects to the company are:• The company is leveraging its unique position in having access to disease relevant tissue from patients for use in efficacy, toxicity or MoA assays• World class team of immunology and drug development experts with access to state of the art equipment• The service division runs bespoke projects for companies that are developing immune targeting drugs (both small and large molecule candidates)• Celentyx has an early stage pipeline of immunotherapeutic programs -
Chief Scientific OfficerAbzena Jul 2013 - Oct 2016San Diego, California, UsKEY CONTRIBUTIONS• Played key role as part of executive management team that raised £20 million in new shares after driving company’s IPO on the AIM with a pre-money valuation of £80 million.• Successfully delivered contract service projects valued at up to £500,000.• Brought diverse science teams together that generated successful outcomes through collaborative programs and synergistic projects. -
Chief Executive Officer / Chief Scientific OfficerAntitope Ltd Dec 2004 - Jul 2013KEY CONTRIBUTIONS:• Grew successful start-up company from a single employee to 45 employees.• Maintained $5.9 million to $10 million in turnover every year, achieving 10%-20% growth throughout tenure.• Increased number of antibody engineering deals 30% by implementing a new downstream technology development program to make manufacturing cell lines; provided integrated solution/platform to drive development of antibody therapeutics. Expanded manufacturing cell line development capacity as a result.• Instumental in managing client projects including six molecules that are inclinical trials, Produced and applied novel antibody humanisation technology to 80+ therapeutic antibodies.• Spearheaded design of 10+ protein therapeutics and cell lines that have entered clinical trials for clients.• Led teams to engineer 60+ novel biopharmaceuticals to reduce immunogenicity. • Secured business from 150+ companies to access proprietary technologies, including 50+ royalty/milestone bearing deals. • Established novel manufacturing cell line development technology platform that generated GMP-ready CHO manufacturing cell lines.
-
Vp Biologics DiscoveryBiovation Jan 2001 - Jun 2004KEY CONTRIBUTIONS:• Developed technology which resulted in several new patents and a platform technology that was provided as a service to the pharma/biotech industry for optimizing drug development.• Spearheaded teams that developed four programs entering clinical trials, and established new technology IP for engineering protein therapeutics.
-
Principal ScientistWhatman Bioscience Jan 2000 - Jan 2001KEY CONTRIBUTIONS:• Provided advanced expertise in genomics and chemistry while successfully completing engineering projects. • Managed a Research Assistant and collaborated with external consultants. • Supervised tooling company suppliers in the production of novel columns used in DNA capture process.Achieved early career success as a Post-Doctoral Research Scientist at the Babraham Institute, Cambridge, UK. Co-wrote an awarded grant, drafted two high-impact publications, and developed a new cell culture technique for the rapid assessment of murine lymphocyte-specific transgenes.
Matthew Baker, Ph.D Skills
Matthew Baker, Ph.D Education Details
-
University Of BirminghamCellular Immunology
Frequently Asked Questions about Matthew Baker, Ph.D
What company does Matthew Baker, Ph.D work for?
Matthew Baker, Ph.D works for Laigo Bio
What is Matthew Baker, Ph.D's role at the current company?
Matthew Baker, Ph.D's current role is Chief Executive Officer.
What is Matthew Baker, Ph.D's email address?
Matthew Baker, Ph.D's email address is ma****@****e.co.uk
What schools did Matthew Baker, Ph.D attend?
Matthew Baker, Ph.D attended University Of Birmingham.
What are some of Matthew Baker, Ph.D's interests?
Matthew Baker, Ph.D has interest in Family, Skydiving, Cycling, Reading.
What skills is Matthew Baker, Ph.D known for?
Matthew Baker, Ph.D has skills like Antibodies, Biotechnology, Assay Development, Monoclonal Antibodies, Drug Discovery, Cell, Immunology, Protein Engineering, Immunoassays, Molecular Biology, Life Sciences, Immunogenicity.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial